Palatin Technologies, a biopharmaceutical company, announced its common stock will transfer from the NYSE American to the Nasdaq Capital Market starting May 29, 2026, continuing under the symbol "PTN." The move aims to increase stock visibility, improve trading liquidity, and attract more institutional investors. Palatin focuses on developing treatments for rare obesity disorders linked to the MC4R pathway, with key drug candidates progressing toward IND submissions in late 2026 and early 2027. Existing shareholders do not need to take any action regarding the listing transfer.
Intel recently sold $20 billion worth of its stock at $95 per share. Since the sale, the stock price has dropped and is now trading below $93. This decline means investors who bought at the offering price are facing immediate losses. The price moveme...
Masayoshi Son holds 67% of SoftBank's U.S. stock portfolio in Intel shares. Despite this large stake, SoftBank did not purchase any additional Intel shares in the last quarter. This suggests a pause or cautious approach in expanding their investment ...
Joseph Devivo, CEO of Butterfly Network, sold 68,346 shares of the company. Insider sales like this can indicate personal financial decisions or strategic moves regarding the company's stock. Investors often watch such transactions closely as they ma...
Chip stocks declined this week not because of any industry-specific news but due to the 30-year Treasury yield reaching its highest level in 19 years. Rising long-term yields often pressure growth stocks like chipmakers, as higher rates increase borr...
Enovix shares fell 18% following the unexpected resignation of CEO Raj Talluri, hitting a record low amid investor concerns. The sudden leadership change has raised questions about the company's manufacturing capabilities and competitive position. Wh...
